ITCI - יחס שווי חברה לקצב צמיחת הרווח Intra-Cellular

Intra-Cellular Therapies (ITCI) is a distinguished leader in neuropharmaceuticals that has earned physician trust through its innovative drug Caplyta for the treatment of schizophrenia. The growth-weighted P/E on the GURU.Markets chart reflects evolving expectations, with the current parameter standing at 0.00. Drug development is accelerating via robotic cell monitoring, while a stable staff of neurobiologists is being augmented by the active hiring of commercial representatives.

The PEG ratio is used to find a balance between asset quality and valuation by comparing the current P/E multiple with earnings growth rates, identifying an undervalued business when the value is below one. In the case of Intra-Cellular Therapies (ITCI), strong pricing power and stable demand for the drug make the growth-adjusted P/E ratio a key indicator of the company's capitalization adequacy.